Declan Doogan - 16 Nov 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
Director
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Nov 2021
Net transactions value
-$3,625
Form type
4
Filing time
17 Nov 2021, 18:03:42 UTC
Previous filing
11 Aug 2021
Next filing
01 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $152,500 +250,000 +67% $0.6100* 623,913 16 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $980,000 +175,000 +28% $5.60* 798,913 16 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $464,500 +50,000 +6.3% $9.29* 848,913 16 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $517,680 +18,000 +2.1% $28.76* 866,913 16 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $1,111,680 +18,000 +2.1% $61.76* 884,913 16 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $324,600 +30,000 +3.4% $10.82* 914,913 16 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $847,800 +18,000 +2% $47.10* 932,913 16 Nov 2021 Direct
transaction BHVN Common Shares Sale $1,441,501 -12,437 -1.3% $115.90* 920,476 16 Nov 2021 Direct F1
transaction BHVN Common Shares Sale $2,127,173 -18,230 -2% $116.69* 902,246 16 Nov 2021 Direct F2
transaction BHVN Common Shares Sale $833,711 -7,073 -0.78% $117.87* 895,173 16 Nov 2021 Direct F3
holding BHVN Common Shares 626,002 16 Nov 2021 By the Declan Doogan 2014 Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Stock Option (Right to buy) Options Exercise $0 -250,000 -100% $0.000000* 0 16 Nov 2021 Common Shares 250,000 $0.6100 Direct F4
transaction BHVN Stock Option (Right to buy) Options Exercise $0 -175,000 -100% $0.000000* 0 16 Nov 2021 Common Shares 175,000 $5.60 Direct F5
transaction BHVN Stock Option (Right to buy) Options Exercise $0 -50,000 -100% $0.000000* 0 16 Nov 2021 Common Shares 50,000 $9.29 Direct F6
transaction BHVN Stock Option (Right to buy) Options Exercise $0 -18,000 -100% $0.000000* 0 16 Nov 2021 Common Shares 18,000 $28.76 Direct
transaction BHVN Stock Option (Right to buy) Options Exercise $0 -18,000 -100% $0.000000* 0 16 Nov 2021 Common Shares 18,000 $61.76 Direct
transaction BHVN Stock Option (Right to buy) Options Exercise $0 -30,000 -100% $0.000000* 0 16 Nov 2021 Common Shares 30,000 $10.82 Direct F7
transaction BHVN Stock Option (Right to buy) Options Exercise $0 -18,000 -100% $0.000000* 0 16 Nov 2021 Common Shares 18,000 $47.10 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 - $116.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.32 - $117.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.33 - $118.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4 The shares underlying this option vested as to 25% of the shares on November 26, 2014, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
F5 The shares underlying this option vested as to 25% of the shares on October 23, 2015, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
F6 The shares underlying this option vested as to 25% of the shares on December 15, 2016, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
F7 The shares underlying this option vested as to 25% of the shares on April 6, 2017, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.